Evidence for immune activation in patients with residual hepatitis C virus RNA long after successful treatment with IFN and ribavirin

References

1. Akdis M., Burgler S., Crameri R., Eiwegger T., Fujita H., Gomez E., Klunker S., Meyer N., O’Mahony L. other authors 2011; Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases. J Allergy Clin Immunol 127:701–721 [View Article][PubMed]
   [Google Scholar]
2. Benjamini Y., Hochberg Y. 1995; Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 57:289–300
   [Google Scholar]
3. Fujiwara K., Allison R. D., Wang R. Y., Bare P., Matsuura K., Schechterly C., Murthy K., Marincola F. M., Alter H. J. 2013; Investigation of residual hepatitis C virus in presumed recovered subjects. Hepatology 57:483–491 [View Article][PubMed]
   [Google Scholar]
4. Ghany M. G., Nelson D. R., Strader D. B., Thomas D. L., Seeff L. B. American Association for Study of Liver Diseases 2011; An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54:1433–1444 [View Article][PubMed]
   [Google Scholar]
5. Haller O., Frese M., Kochs G. 1998; Mx proteins: mediators of innate resistance to RNA viruses. Rev Sci Tech 17:220–230[PubMed]
   [Google Scholar]
6. Jacobson I. M., Cacoub P., Dal Maso L., Harrison S. A., Younossi Z. M. 2010; Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol 8:1017–1029 [View Article][PubMed]
   [Google Scholar]
7. Jimenez-Sousa M. A., Almansa R., de la Fuente C., Caro-Paton A., Ruiz L., Sanchez-Antolín G., Gonzalez J. M., Aller R., Alcaide N. other authors 2010; Increased Th1, Th17 and pro-fibrotic responses in hepatitis C-infected patients are down-regulated after 12 weeks of treatment with pegylated interferon plus ribavirin. Eur Cytokine Netw 21:84–91[PubMed]
   [Google Scholar]
8. Kisiel E., Radkowski M., Pawelczyk A., Horban A., Stanczak J., Bukowska-Ośko I., Caraballo Cortes K., Kaźmierczak J., Popiel M., Laskus T. 2014; Seronegative hepatitis C virus infection in patients with lymphoproliferative disorders. J Viral Hepat 21:424–429 [View Article][PubMed]
   [Google Scholar]
9. Laskus T., Radkowski M., Wang L. F., Nowicki M., Rakela J. 2000; Uneven distribution of hepatitis C virus quasispecies in tissues from subjects with end-stage liver disease: confounding effect of viral adsorption and mounting evidence for the presence of low-level extrahepatic replication. J Virol 74:1014–1017 [View Article][PubMed]
   [Google Scholar]
10. Livak K. J., Schmittgen T. D. 2001; Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods 25402–408 [CrossRef]
    [Google Scholar]
11. Machida K., Cheng K. T., Sung V. M., Levine A. M., Foung S., Lai M. M. 2006; Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6. J Virol 80:866–874 [View Article][PubMed]
    [Google Scholar]
12. Moser B., Loetscher P. 2001; Lymphocyte traffic control by chemokines. Nat Immunol 2:123–128 [View Article][PubMed]
    [Google Scholar]
13. Pearlman B. L., Traub N. 2011; Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 52:889–900 [View Article][PubMed]
    [Google Scholar]
14. Pham T. N., MacParland S. A., Mulrooney P. M., Cooksley H., Naoumov N. V., Michalak T. I. 2004; Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 78:5867–5874 [View Article][PubMed]
    [Google Scholar]
15. Pham T. N., Mercer S. E., Michalak T. I. 2009; Chronic hepatitis C and persistent occult hepatitis C virus infection are characterized by distinct immune cell cytokine expression profiles. J Viral Hepat 16:547–556 [View Article][PubMed]
    [Google Scholar]
16. Quiroga J. A., Martín J., Navas S., Carreño V. 1998; Induction of interleukin-12 production in chronic hepatitis C virus infection correlates with the hepatocellular damage. J Infect Dis 178:247–251 [View Article][PubMed]
    [Google Scholar]
17. Radkowski M., Gallegos-Orozco J. F., Jablonska J., Colby T. V., Walewska-Zielecka B., Kubicka J., Wilkinson J., Adair D., Rakela J., Laskus T. 2005; Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 41106–114 [CrossRef]
    [Google Scholar]
18. Saleh M. G., Tibbs C. J., Koskinas J., Pereira L. M., Bomford A. B., Portmann B. C., McFarlane I. G., Williams R. 1994; Hepatic and extrahepatic hepatitis C virus replication in relation to response to interferon therapy. Hepatology 20:1399–1404 [View Article][PubMed]
    [Google Scholar]
19. Viganò S., Perreau M., Pantaleo G., Harari A. 2012; Positive and negative regulation of cellular immune responses in physiologic conditions and diseases. Clin Dev Immunol 2012:485781 [View Article][PubMed]
    [Google Scholar]
20. Wilkinson J., Radkowski M., Eschbacher J. M., Laskus T. 2010; Activation of brain macrophages/microglia cells in hepatitis C infection. Gut 59:1394–1400 [View Article][PubMed]
    [Google Scholar]
21. Zignego A. L., Giannini C., Gragnani L. 2012; HCV and lymphoproliferation. Clin Dev Immunol 2012:980942 [View Article][PubMed]
    [Google Scholar]